Planning and evaluation is an active process at the Ohio State University Comprehensive Cancer Center. A University-based long range plan is being developed and carried out by a renowned management consulting firm, Deloitte and Touche. The planning effort culminated in a retreat of the Project Steering Committee which identified the key issues for a five year plan. The strategic plan for the CCC-CHRI resulted from this planning process. The key areas of the plan are research, patient care, education, organization and management, human and financial resources. The External Advisory Committee (EAC) is composed of Dr. Carlo Croce, Dr. C. Russell de Burlo, Dr. Richard Rifkind, Dr. Thomas R. Tritton, Dr. Frederick Valeriote, Dr. Daniel Van Hoff and Dr. Ernst L. Wynder. This distinguished group meets annually to discuss planning, management of programs, and administration. The Committee reports directly to Dr. Schuller but meets also with Center Senior Leaders and University officials during its annual site visit. The Internal Advisory Committee (IAC) consists of Deans of the various Colleges in which the OSUCCC Programs are conducted. This committee, which is chaired by the Associate Vice President for Health Services, Dr. Ronald L. St. Pierre, meets three times yearly. The CCC-member advisory committees include the Committees for Space Allocation, Basic Research, Clinical Research, Community Research, Research Development Award Committee, and Clinical Scientific Review Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-22
Application #
5206774
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
22
Fiscal Year
1996
Total Cost
Indirect Cost
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications